JACC-Heart Failure

Papers
(The H4-Index of JACC-Heart Failure is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality163
Advanced Heart Failure151
A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock133
Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis126
Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease123
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF116
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction112
Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction105
COVID-19 Illness and Heart Failure100
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction97
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes85
Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-1985
Reassessing Recipient Mortality Under the New Heart Allocation System80
Considerations for Heart Failure Care During the COVID-19 Pandemic74
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan74
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists74
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction71
COVID-19 in Heart Transplant Recipients66
Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy64
Sacubitril/Valsartan64
Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community64
Advanced Heart Failure Epidemiology and Outcomes57
Clinical Role of CA125 in Worsening Heart Failure57
Care Gaps in Adherence to Heart Failure Guidelines54
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy52
Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation51
Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes51
Natriuretic Peptides as Inclusion Criteria in Clinical Trials51
Percutaneous Left Axillary Artery Placement of Intra-Aortic Balloon Pump in Advanced Heart Failure Patients51
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes50
End-Stage Heart Failure With COVID-1950
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause50
Heart Transplantation49
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure48
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF47
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction47
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF45
Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection Fraction44
Hemocompatibility-Related Adverse Events and Survival on Venoarterial Extracorporeal Life Support44
Health Literacy and Outcomes Among Patients With Heart Failure44
Impaired Exercise Tolerance in Heart Failure With Preserved Ejection Fraction44
Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients44
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction42
0.039322137832642